Latest Insider Transactions at Axcella Health Inc. (AXLA)
This section provides a real-time view of insider transactions for Axcella Health Inc. (AXLA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Axcella Health Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Axcella Health Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
679
-2.66%
|
$0
$0.58 P/Share
|
|
Feb 10
2023
|
Paul Fehlner SVP & Chief Legal Officer |
BUY
Open market or private sale
|
Direct |
5,221
+8.25%
|
$0
$0.66 P/Share
|
|
Oct 19
2022
|
William Hinshaw President & CEO |
SELL
Open market or private sale
|
Direct |
16,000
-16.32%
|
$16,000
$1.56 P/Share
|
|
Oct 17
2022
|
William Hinshaw President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+33.78%
|
-
|
|
Oct 13
2022
|
Societe Des Produits Nestle S.A. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,658,536
+24.78%
|
$3,658,536
$1.64 P/Share
|
|
Oct 13
2022
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,383,760
+22.62%
|
$10,383,760
$1.64 P/Share
|
|
Sep 06
2022
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
547
-2.1%
|
$1,094
$2.52 P/Share
|
|
Jun 01
2022
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
590
-2.21%
|
$1,180
$2.01 P/Share
|
|
May 19
2022
|
David R Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
47,059
+18.32%
|
-
|
|
Mar 18
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+0.93%
|
-
|
|
Mar 16
2022
|
Robert Crane Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
39,267
+50.0%
|
$39,267
$1.91 P/Share
|
|
Mar 16
2022
|
David R Epstein Director |
BUY
Open market or private purchase
|
Direct |
26,178
+13.97%
|
$26,178
$1.91 P/Share
|
|
Mar 16
2022
|
Paul Fehlner SVP & Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
10,471
+33.48%
|
$10,471
$1.91 P/Share
|
|
Mar 16
2022
|
William Hinshaw President & CEO |
BUY
Open market or private purchase
|
Direct |
13,089
+21.42%
|
$13,089
$1.91 P/Share
|
|
Mar 16
2022
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,319,371
+29.61%
|
$6,319,371
$1.91 P/Share
|
|
Mar 16
2022
|
Societe Des Produits Nestle S.A. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,141,361
+29.67%
|
$3,141,361
$1.91 P/Share
|
|
Mar 01
2022
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
553
-2.03%
|
$553
$1.86 P/Share
|
|
Feb 18
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,534
+1.12%
|
-
|
|
Jan 31
2022
|
William Hinshaw President & CEO |
SELL
Open market or private sale
|
Direct |
16,590
-33.18%
|
$16,590
$1.65 P/Share
|
|
Jan 28
2022
|
William Hinshaw President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
-
|
|
Jan 18
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+1.14%
|
-
|
|
Dec 17
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+1.15%
|
-
|
|
Nov 18
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,534
+1.16%
|
-
|
|
Oct 18
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+1.18%
|
-
|
|
Sep 17
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+1.19%
|
-
|
|
Aug 18
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,534
+1.2%
|
-
|
|
Aug 13
2021
|
Gary P. Pisano Director |
BUY
Exercise of conversion of derivative security
|
Direct |
81,433
+50.0%
|
$0
$0.28 P/Share
|
|
Jul 16
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+1.22%
|
-
|
|
Jun 18
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+1.24%
|
-
|
|
May 18
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,534
+1.25%
|
-
|
|
Apr 18
2021
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+1.27%
|
-
|
|
Feb 01
2021
|
Manu Chakravarthy SVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,472
-30.79%
|
$92,360
$5.5 P/Share
|
|
Feb 01
2021
|
Manu Chakravarthy SVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+50.0%
|
-
|
|
Oct 30
2020
|
Laurent Chardonnet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,601
+29.33%
|
$7,803
$3.6 P/Share
|
|
May 18
2020
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,800,000
+30.05%
|
$15,200,000
$4.75 P/Share
|
|
May 13
2019
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+33.65%
|
$10,000,000
$20.0 P/Share
|
|
May 13
2019
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,533,974
+22.85%
|
-
|